الفهرس 
Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Necrotizing enterocolitis is a devastating inflammatory bowel disease of neonates, characterized by ischemic necrosis of the intestinal mucosa, which affects mostly premature infants. It remains the most threatening gastrointestinal complication of prematurity leading to high mortality and morbidity with substantial medical burdens to both families and society. Major advances in genomic research, paved the way for studies that began to reveal the contribution of genetics to NEC. Chemerin and visfatin are among these genes while chemerin is one of adipokines acting as a potent chemotactic factor for macrophages, natural killer cells and immature dendritic cells, which result in chemotaxis to sites of tissue injury and inflammation. And visfatin that can be considered a new proinflammatory adipocytokine, upregulating the production of pro- and anti-inflammatory cytokines. Thus, our aim in the current study is to evaluate chemerin and visfatin mRNA expression in newborns with necrotizing enterocolitis to help in early prediction and management.
This prospective case-control study collected cases diagnosed as NEC from NICUs of Menoufia, Beheira and Fayoum governments in the period from October 2020 till October 2021. This study included 140 neonates divided into two groups:
group I (cases): Includes 70 newborns (52 male,18 female) diagnosed with proven or complicated necrotizing enterocolitis fulfilling all inclusion and exclusion criteria.
group II (control group): Include 70 healthy newborns (47 male, 23 female) as a control group.